Clinical Trial Update: Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of tislelizumab and SBRT for head and neck squamous cell carcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC | Phase 2 | Status: RECRUITING